|
| Takeda gets US FDA response letter for FDC of alogliptin, Actos to treat type 2 diabetes |
5 Sep 09, 06:51 |
|
| Takeda Pharmaceutical Company Limited announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (US), received on September 2nd a complete response letter from the US Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and Actos (pioglitazone HCl). |
| more |
|
